Mary Tilley Jenkins Vogel, M.D. ...

Dr. Mary T Jenkins Vogel, MD

Claim this profile

NorthShore University HealthSystem-Evanston Hospital

Studies Ovarian Cancer
Studies Ovarian Carcinoma
13 reported clinical trials
42 drugs studied

Area of expertise

1

Ovarian Cancer

Mary T Jenkins Vogel, MD has run 7 trials for Ovarian Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Ovarian Carcinoma

Mary T Jenkins Vogel, MD has run 5 trials for Ovarian Carcinoma. Some of their research focus areas include:

Stage I
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.

NorthShore University HealthSystem-Evanston Hospital

Image of trial facility.

NorthShore University HealthSystem-Highland Park Hospital

Clinical Trials Mary T Jenkins Vogel, MD is currently running

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

More about Mary T Jenkins Vogel, MD

Clinical Trial Related

8 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Mary T Jenkins Vogel, MD has experience with

  • Carboplatin
  • Paclitaxel
  • Olaparib
  • Pembrolizumab
  • Biospecimen Collection
  • Cediranib Maleate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Mary T Jenkins Vogel, MD specialize in?

Is Mary T Jenkins Vogel, MD currently recruiting for clinical trials?

Are there any treatments that Mary T Jenkins Vogel, MD has studied deeply?

What is the best way to schedule an appointment with Mary T Jenkins Vogel, MD?

What is the office address of Mary T Jenkins Vogel, MD?

Is there any support for travel costs?